Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995979 | 1.00 | CYP1A2 (0.44) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL2995971 | 0.89 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL5147272 | 0.88 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL32662599 | 0.88 | CYP1A2 (0.46) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL28102381 | 0.86 | ALDH1A1 (0.46) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL2993627 | 0.85 | CYP1A2 (0.44) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL2993625 | 0.85 | CYP1A2 (0.44) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL27573003 | 0.84 | TSHR (0.46) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL8489171 | 0.82 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD | |
| SCHEMBL8489175 | 0.82 | CYP1A2 (0.42) | CYP1A2PTGDR2ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332048-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | KALA PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-11091487-B2 | Meropenem derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-2968274-B1 | MEROPENEM DERIVATIVES AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10392388-B2 | Meropenem derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170349590-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | OXFORD FINANCE LLC | 2017-12-07 | — | — | US | disclosed |
| US-9725451-B2 | Meropenem derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160039823-A1 | Meropenem Derivatives and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2968274-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144285-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-07-22 | — | — | US | disclosed |
| US-7101912-B2 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XENOPORT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XIANG JIA-NING (US) | 2004-08-26 | — | — | US | disclosed |
| CN-1075062-C | Acetic acid derivatives | HOFFMANN LA ROCHE (CH) | 2001-11-21 | — | — | CN | disclosed |
| EP-0830372-B1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | UNIV KANSAS (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0830372-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997039024-A1 | CYCLIC PRODRUGS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS HAVING IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | THE UNIVERSITY OF KANSAS (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5672584-A | MODIFIED WITH END GROUPS | THE UNIVERSITY OF KANSAS (US) | 1997-09-30 | — | — | US | disclosed |
| CN-1112104-A | Acetic acid derivatives | HOFFMANN LA ROCHE (CH) | 1995-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039823-A1 | Meropenem Derivatives and Uses Thereof | SLCO1B1, SLCO2B1, ABCB11 | CYP1A2 246/4885PTGDR2 3057/4885ALDH1A1 2014/4885 |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | PDE3A, ADORA2A, CDA | CYP1A2 223/4885PTGDR2 40/4885ALDH1A1 606/4885 |
| US-10392388-B2 | Meropenem derivatives and uses thereof | SLCO1B1, SLCO2B1, ABCB11 | CYP1A2 246/4885PTGDR2 3057/4885ALDH1A1 2014/4885 |
| US-20170349590-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | SLCO1B1, SLCO2B1, ABCB11 | CYP1A2 246/4885PTGDR2 3057/4885ALDH1A1 2014/4885 |
| US-20210332048-A1 | MEROPENEM DERIVATIVES AND USES THEREOF | SLCO1B1, SLCO2B1, ABCB11 | CYP1A2 246/4885PTGDR2 3057/4885ALDH1A1 2014/4885 |
| US-11091487-B2 | Meropenem derivatives and uses thereof | SLCO1B1, SLCO2B1, ABCB11 | CYP1A2 246/4885PTGDR2 3057/4885ALDH1A1 2014/4885 |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | RARA, RARB, RARG | CYP1A2 390/4885PTGDR2 1328/4885ALDH1A1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.